Correspondence 0001193125-24-080366 from ASLAN Pharmaceuticals Ltd (CIK 0001722926)
ASLAN Pharmaceuticals Ltd (CIK 0001722926)
Date: March 28, 2024 · CIK: 0001722926 · Accession: 0001193125-24-080366
AI Filing Summary & Sentiment
File numbers found in text: 333-278217
Letter
CORRESPONDENCE
ASLAN Pharmaceuticals Limited
3 Temasek Avenue
Level 18 Centennial Tower
Singapore 039190
March 28,
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attn: Jimmy McNamara
Re: ASLAN Pharmaceuticals Limited
Registration Statement on Form F-3
File No. 333-278217
Acceleration Request
Requested Date: Friday, March 29, 2024
Requested Time: 4:00 P.M. Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, ASLAN Pharmaceuticals Limited (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form F-3 to become effective on Friday, March 29, 2024, at 4:00 P.M. Eastern Time, or as soon thereafter as is practicable, or at such later time as its counsel may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes each of Carlos Ramirez and Edmond Lay of Cooley LLP, counsel to the Registrant, to make such request on its behalf.
Once the above-referenced Registration Statement has been declared effective, please orally confirm that event with Carlos Ramirez of Cooley LLP at (858) 550-6157, or in his absence, Edmond Lay of Cooley LLP at (858) 550-6166. Thank you for your assistance with this matter.
Sincerely,
ASLAN Pharmaceuticals Limited
Show Raw Text
CORRESP 1 filename1.htm CORRESPONDENCE ASLAN Pharmaceuticals Limited 3 Temasek Avenue Level 18 Centennial Tower Singapore 039190 March 28, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Jimmy McNamara Re: ASLAN Pharmaceuticals Limited Registration Statement on Form F-3 File No. 333-278217 Acceleration Request Requested Date: Friday, March 29, 2024 Requested Time: 4:00 P.M. Eastern Time Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, ASLAN Pharmaceuticals Limited (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form F-3 to become effective on Friday, March 29, 2024, at 4:00 P.M. Eastern Time, or as soon thereafter as is practicable, or at such later time as its counsel may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes each of Carlos Ramirez and Edmond Lay of Cooley LLP, counsel to the Registrant, to make such request on its behalf. Once the above-referenced Registration Statement has been declared effective, please orally confirm that event with Carlos Ramirez of Cooley LLP at (858) 550-6157, or in his absence, Edmond Lay of Cooley LLP at (858) 550-6166. Thank you for your assistance with this matter. Sincerely, ASLAN Pharmaceuticals Limited By: /s/ Carl Firth, Ph.D. Carl Firth, Ph.D. Chief Executive Officer cc: Kiran Asarpota, ASLAN Pharmaceuticals Limited Carlos Ramirez, Cooley LLP Edmond Lay, Cooley LLP